Search company, investor...
Search
SK Life Science company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

sklifescienceinc.com

Founded Year

1993

About SK Life Science

SK Life Science is a global CNS-focused pharmaceutical company that promises to go beyond the expected to serve those affected by CSN disorders.

SK Life Science Headquarters Location

461 From Road 5th Floor

Paramus, New Jersey, 17652,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest SK Life Science News

Xcopri provides long-term seizure control in patients with focal epilepsy

Jun 23, 2022

ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact customerservice@slackinc.com . Back to Healio Long-term use of Xcopri was safe and reduced seizures by more than 90% in adults with uncontrolled focal seizures, according to results of an open-label extension study published in Neurology. “The findings show that the notable improvement in seizure control that was seen in patients with uncontrolled focal epilepsy is sustained over long term,” Pavel Klein, MD, lead study author and epileptologist and neurologist at Mid-Atlantic Epilepsy and Sleep Center in Bethesda, Md., told Healio. “The study shows that a significant proportion of patients with uncontrolled epilepsy continue to remain seizure-free or have at least 90% reduction for a period of time that sustained over the duration of the study — for years.” Source: Adobe Stock. Klein and colleagues conducted a randomized, double-blind, placebo-controlled study of Xcopri (cenobamate, SK Life Science Inc.) and assessed data from 355 adult patients with focal seizures that were uncontrolled despite being treated with up to three antiseizure medications. According to a press release about the study findings from SK Life Science, participants, who had at least eight seizures during the 8-week baseline period, completed the 18-week, double-blind phase and continued into the open-label extension. The median treatment duration of cenobamate was 54 months (200 mg median daily dose, ranging from 50-400 mg). As of July 2019, 59% of patients (209 of 355) continued treatment. During any 12-month period of the study, 13% to 16% of patients achieved seizure freedom, and among those, the median seizure-free duration during each 12-month interval was 48 months, 47.2 months and 45.1 months, the company reported in the release. The study showed that all patients taking cenobamate experienced a median percent seizure frequency reduction over baseline that increased with each 6-month interval, up to 76% during months 43 to 48 of the study. Researchers further reported that 16.4% of patients achieved 100% seizure reduction during 36 to 48 months, and 39.1% of patients achieved more than 90% seizure reduction during the same period. SK Life Science said in the release that no new safety issues were reported. Treatment was discontinued in 141 patients, with the most common reasons being a lack of efficacy (17%), withdrawal by patient (9%) and adverse events (8%). The most common treatment-related adverse events were dizziness, somnolence, fatigue and headache. “The realization that we now have a medication that can bring about sustained seizure freedom for patients with uncontrolled focal epilepsy is very exciting and life-changing for patients who have that response,” Klein said. “It is a wonderful thing to be able to offer to patients.” Reference: Long-term efficacy and safety data of Xcopri (cenobamate tablets) CV published in Neurology. https://www.sklifescienceinc.com/pdf/Long_Term_Efficacy_and_Safety_Data_of_XCOPRI%C2%AE_cenobamate_tablets_CV_Published_in_Neurology.pdf . Published June 22, 2022. Accessed June 23, 2022. Read more about

SK Life Science Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

SK Life Science Rank

  • When was SK Life Science founded?

    SK Life Science was founded in 1993.

  • Where is SK Life Science's headquarters?

    SK Life Science's headquarters is located at 461 From Road, Paramus.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.